欧阳运洁,刘利民,戴广海,罗晶

• 1:中国人民解放军第九二一医院肿瘤科
• 2:中国人民解放军总医院肿瘤科

摘要(Abstract)：

目的探讨晚期十二指肠癌一线化疗联合抗血管生成药物贝伐珠单抗治疗的临床疗效和安全性。方法回顾性分析83例一线接受氟尿嘧啶为基础的化疗的晚期初治十二指肠癌患者的临床病理资料和生存情况。根据患者一线化疗是否联合贝伐珠单抗,将患者分为贝伐珠单抗联合化疗组(n=19)与单纯化疗组(n=64)。比较两组治疗疗效、无进展生存期以及不良反应发生率。结果贝伐珠单抗联合化疗组与单纯化疗组客观缓解率分别为52.6%和23.4%(P=0.043),疾病控制率分别为73.6%和50.0%(P=0.039)。贝伐珠单抗联合化疗组的中位无进展生存期长于单纯化疗组(8.0个月vs 5.0个月,P=0.012)。贝伐珠单抗联合化疗组患者高血压和蛋白尿发生率高于单纯化疗组(均P<0.05),在血液学毒性、消化道反应和脏器功能等方面比较,差异均无统计学意义(均P>0.05)。结论一线化疗方案联合贝伐珠单抗治疗十二指肠癌患者无进展生存期延长,不良反应可耐受。

关键词(KeyWords)： 十二指肠肿瘤/药物疗法;氟尿嘧啶/治疗应用;抗体,单克隆/治疗应用;抗肿瘤联合化疗方案/治疗应用;治疗结果;回顾性研究

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 欧阳运洁,刘利民,戴广海,罗晶

DOI: 10.13267/j.cnki.syzlzz.2019.06.009

参考文献(References)：

• [1] Bilimoria KY,Bentrem DJ,Wayne JD,et al.Small bowel cancer in the United States:changes in epidemiology,treatment,and survival over the last 20 years[J].Ann Surg,2009,249(1):63.
• [2] Puccini A,Battaglin F,Lenz HJ.Management of advanced small bowel cancer[J].Curr Treat Options Oncol,2018,19(12):69.
• [3] Overman MJ,Varadhachary GR,Kopetz S,et al.Phase Ⅱ study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater[J].J Clin Oncol,2009,27(16):2598-2603.
• [4] Overman MJ.Rare but real:management of small bowel adenocarcinoma[M]//2013 ASCO Educational Book.Alexandria:ASCO,2016:189-193.
• [5] Horimatsu T,Nakayama N,Moriwaki T,et al.A phase Ⅱ study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma[J].Int J Clin Oncol,2017,22(5):905-912.
• [6] Mcwilliams RR,Foster NR,Mahoney MR,et al.North Central Cancer Treatment Group N0543 (Alliance):A phase 2 trial of pharmacogenetic-based dosing of irinotecan,oxaliplatin,and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma[J].Cancer,2017,123(7):145-150.
• [7] 万德森,张苏展,陈玉泽,等.贝伐珠单抗联合以5-FU为基础的双药化疗用于结直肠癌仅肝转移患者新辅助治疗:一项多中心单臂研究[J].实用肿瘤杂志,2018,33(1):41-46.
• [8] Cassidy J,Clarke S,Diaz-Rubio E,et al.Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer[J].J Clin Oncol,2008,26(12):2006-2012.
• [9] Forbes SA,Bindal N,Bamford S,et al.COSMIC:mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer[J].Nucleic Acids Res,2011,39(Database issue):D945-950.
• [10] Santini D,Fratto ME,Spoto C,et al.Cetuximab in small bowel adenocarcinoma:a new friend?[J].Br J Cancer,2010,103(8):1305;author reply 1306.
• [11] Winter KS,Hofmann FO,Thierfelder KM,等.基于实体瘤疗效评价标准1.1版(RECIST1.1)中的体积阈值:肝转移瘤治疗效果评估[J].国际医学放射学杂志,2019,42(1):121.
• [12] Ellis LM,Hicklin DJ.VEGF-targeted therapy:mechanisms of anti-tumour activity[J].Nat Rev Cancer,2008,8(8):579-591.
• [13] Huang J,Kelly CP,Bakirtzi K,et al.Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis[J].Nat Microbiol,2018,121(5):135-139.
• [14] Overman MJ,Pozadzides J,Kopetz S,et al.Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine[J].Br J Cancer,2010,102(1):144-150.
• [15] Von Rahden BH,Brucher BL,Langner C,et al.Expression of cyclo-oxygenase 1 and 2,prostaglandin E synthase and transforming growth factor beta1,and their relationship with vascular endothelial growth factors A and C,in primary adenocarcinoma of the small intestine[J].Br J Surg,2006,93(11):1424-1432.
• [16] Ferrara N,Hillan KJ,Gerber HP,et al.Discovery and development of bevacizumab,an anti-VEGF antibody for treating cancer[J].Nat Rev Drug Discov,2004,3(5):391-400.
• [17] Saltz LB,Clarke S,Diaz-Rubio E,et al.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase Ⅲ study[J].J Clin Oncol,2008,26(12):2013-2019.
• [18] Gulhati P,Raghav K,Shroff RT,et al.Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater:A single-center,open-label,phase 2 study[J].Cancer,2017,123(6):1011-1017.